上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
15期
25-27
,共3页
美沙拉嗪%溃疡性结肠炎%炎症因子%血小板
美沙拉嗪%潰瘍性結腸炎%炎癥因子%血小闆
미사랍진%궤양성결장염%염증인자%혈소판
mesalazine%ulcerative colitis%inlfammatory factor%platelet
目的:考察美沙拉嗪对活动性溃疡性结肠炎患者炎症相关因子和血小板计数的影响。方法:将89例活动性溃疡性结肠炎患者分为观察组(美沙拉嗪肠溶片治疗,45例)和对照组(柳氮磺胺吡啶治疗,44例),比较两组治疗效果和不良反应发生情况。结果:治疗后,观察组患者治疗有效率(93.33%)明显高于对照组(70.45%),而观察组炎症指标(IL-6、IL-1、TNF-α)和血小板计数均明显低于对照组,两组比较差异具有统计学意义(P<0.05),且全部患者治疗后的上述指标水平较治疗前均明显降低,治疗前后比较差异均具有显著性(P<0.05);治疗过程中,观察组不良反应发生比例明显低于对照组(P<0.05)。结论:美沙拉嗪对活动性溃疡性结肠炎具有确切的治疗效果,可明显降低患者炎症因子水平和抑制血小板活化状态。
目的:攷察美沙拉嗪對活動性潰瘍性結腸炎患者炎癥相關因子和血小闆計數的影響。方法:將89例活動性潰瘍性結腸炎患者分為觀察組(美沙拉嗪腸溶片治療,45例)和對照組(柳氮磺胺吡啶治療,44例),比較兩組治療效果和不良反應髮生情況。結果:治療後,觀察組患者治療有效率(93.33%)明顯高于對照組(70.45%),而觀察組炎癥指標(IL-6、IL-1、TNF-α)和血小闆計數均明顯低于對照組,兩組比較差異具有統計學意義(P<0.05),且全部患者治療後的上述指標水平較治療前均明顯降低,治療前後比較差異均具有顯著性(P<0.05);治療過程中,觀察組不良反應髮生比例明顯低于對照組(P<0.05)。結論:美沙拉嗪對活動性潰瘍性結腸炎具有確切的治療效果,可明顯降低患者炎癥因子水平和抑製血小闆活化狀態。
목적:고찰미사랍진대활동성궤양성결장염환자염증상관인자화혈소판계수적영향。방법:장89례활동성궤양성결장염환자분위관찰조(미사랍진장용편치료,45례)화대조조(류담광알필정치료,44례),비교량조치료효과화불량반응발생정황。결과:치료후,관찰조환자치료유효솔(93.33%)명현고우대조조(70.45%),이관찰조염증지표(IL-6、IL-1、TNF-α)화혈소판계수균명현저우대조조,량조비교차이구유통계학의의(P<0.05),차전부환자치료후적상술지표수평교치료전균명현강저,치료전후비교차이균구유현저성(P<0.05);치료과정중,관찰조불량반응발생비례명현저우대조조(P<0.05)。결론:미사랍진대활동성궤양성결장염구유학절적치료효과,가명현강저환자염증인자수평화억제혈소판활화상태。
To study the effect of mesalazine on inlfammation-associated cytokines and platelet count in patients with active ulcerative colitis. Methods:Eighty-nine cases of patients with active ulcerative colitis were divided into an observation group (treated with mesalazine tablets, n=45) and a control group (treated with sulfasalazine, n=44) and the effects and adverse reaction were compared between two groups. Results:After treatment, the efifciency was signiifcantly higher in the observation group (93.33%) than in the control group (70.45%), and the inlfammation markers such as IL-6, IL-1, TNF-αand the platelet count were signiifcantly lower in the observation group than in the control group (P<0.05), moreover, index levels above-mentioned in all patients were signiifcantly decreased after treatment as compared with those before treatment (P<0.05). Adverse reaction was significantly lower in the observation group than in the control group (P<0.05) during treatment. Conclusion:Mesalazine has a good effect in the treatment of active ulcerative colitis and can signiifcantly decrease the levels of inlfammatory factors and inhibit the activation of platelet in patients.